1. ProMetic Life Sciences Inc. Financial Results Q1-2011 June 15, 2011 TSX:PLI 1

2. ProMetic Life Sciences Inc. 2 Introduction – Forward Looking StatementFinancials Q1 2011Therapeutics Business Review & OutlookProtein Technologies Business Review & OutlookSummaryQ&A

3. ProMetic - 4 Opportunities : 1 Company 3

4. Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking statements about ProMetic’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 24 of ProMetic’s Annual Information Form for the year ended December 31, 2010, under the heading “Risk Factors”. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise. Copyright notice The information contained in this presentation (including names, images, logos and descriptions portraying ProMetic's products and/or services) is the property of ProMetic Life Sciences Inc., of its divisions and / or of its subsidiaries (“ProMetic”) and is protected by copyright, patent and trademark law and / or other intellectual property rights. Neither this presentation nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including printing and photocopying, or by any information storage or retrieval system without prior permission in writing from ProMetic. Disclaimer ProMetic reserves the right to make improvements, corrections and/or changes to this presentation at any time. 4 4

5. ProMetic Life Sciences Inc. 5 Introduction – Forward Looking StatementFinancials Q1 2011Therapeutics Business Review & OutlookProtein Technologies Business Review & OutlookSummaryQ&A

6. Source of Financial Information The following information is derived from the financial information of the Company for each of the two most recently completed financial years. The financial statements are, for the first time, prepared in accordance with International Financial Reporting Standards (IFRS). More financial information, including the Company’s Annual Information Form, is available on SEDAR (www.sedar.com). All tabulated sums in CAD 000’s except for “per share” amounts.www.sedar.com 6

7. International Financial Reporting Standards (IFRS) Transition to and initial adoption of IFRS Starting January 1, 2011, the Corporation has applied IFRS as issued by the International Accounting Standards Board [“IASB”]. The preparation of the condensed unaudited interim consolidated financial statements for the three-month period ending March 31, 2011 includes the initial adoption of accounting policies under IFRS which are different than the accounting policies used to prepare the most recent annual consolidated financial statements prepared under Canadian generally accepted accounting principles [“GAAP”]. The accounting policies as set out in note 2 to the condensed unaudited interim consolidated financial statements for the three-month period ended March 31, 2011 have been applied consistently to all periods beginning on or after January 1, 2010 presented in these financial statements. Comparative information for the three-month period ended March 31, 2010 and financial statements for the year ended December 31, 2010, have thus been adjusted from amounts previously reported under Canadian GAAP. They also have been applied in preparing an opening IFRS balance sheet at January 1, 2010 for the purpose of the transition to IFRS, as required by IFRS 1, First-time Adoption of International Financial Reporting Standards. A reconciliation of previously reported periods in accordance with Canadian GAAP to IFRS, as well as an explanation of how the transition from Canadian GAAP to IFRS has affected our financial position, financial performance and cash flows are provided in note 19 to the condensed unaudited interim consolidated financial statements. Impact of IFRS on our Corporation The conversion to IFRS impacts the way we present our financial results. The impact of the conversion to IFRS on our accounting systems has been minimal due to limited changes in accounting policies. Our internal and disclosure control processes, as currently designed, have not required significant modifications as a result of conversion to IFRS. We have assessed the impact of adopting IFRS on our contractual arrangements, and have not identified any material compliance issues. We have also considered the impact that the transition will have on our internal planning process and compensation arrangements and have not identified any significant issues. 7

8. Revenue Analysis – Q1 Quarter ended 31 March * 2011 CAD 000s 2010 CAD 000s Change Service & Licence Fees 2,411367+ 556.9 % Product Sales 4072,636- 84.5 % Total 2,8183,002- 6.1 % *2010 as restated for IFRS 8

9. Cost Analysis – Q1 Quarter ended 31 March * 2011 CAD 000s 2010 CAD 000s Change Cost of Goods Sold 415998- 58.4 % Total R&D 2,9973,074- 2.5 % Admin & Marketing 1,5741,515 + 3.9 % Exchange Movement (261)147- 277.6% *2010 as restated for IFRS 9

10. Business Segment Performance for Q1 Quarter ended 31 March * Profit / (Loss) 2011 CAD 000s 2010 CAD 000s Change Therapeutics (563)(163)**+ 245.4 % Protein Technologies (395)(901)- 56.16% Corporate (1,720)(2,064)- 16.7 % Total Profit / (Loss) (2,678)(3,128)- 14.4% *2010 as restated for IFRS ** 2010 includes a one-off gain of $251 in relation to an insurance claim 10

11. Performance Comparison Quarter ended 31 March * 2011 CAD 000s 2010 CAD 000s Change Revenues 2,8183,002- 6.1 % Net Loss (2,678)(3,128)- 14.4 % Net Loss per share (basic and diluted) 0.01 0% Issued and Fully Paid Common Shares 357,672,838349,593,400+ 2.3 % EBITDA** (1,725)(2,560)- 32.6 % *2010 as restated for IFRS **EBITDA is a non-GAAP measure, employed by the company to monitor its performance. Therefore it is unlikely to be comparable to similar measures presented by other companies. The company calculates its EBITDA by subtracting from Revenues, its Cost of Goods Sold, excluding amortization of capital assets, its Research and Development Expenses Rechargeable and Non-Rechargeable as well as its Administration and Marketing Expenses. 11

12. Balance Sheet Quarter-end cash balance augmented by post balance-sheet funding initiatives Advances from Shareholders of $2,240k represents sums received by way of equity investment for which the associated shares were not issued at quarter-end. These sums are not repayable. –$1,500k relates to investments in Newco –$740k relates to a PIPE in PLI closed in April, and for which shares were issued in April Deferred Revenues includes USD 8,000k in relation to the extinguishment of the Celgene debt. USD 2,000k will be released in Q2, with the remaining USD 6,000k anticipated to be released in H2 as the associated milestones are met. As a result, Long-term debt, at fair value, reduced from $13,762k at 31 December 2010 to $ 2,952k at quarter-end. 12

13. Post-Balance Sheet Events During April 2011, the Company closed a series of equity issuances by way of private placements totalling $2,750, of which $2,010 was received in April, 2011. These issuances were done at an average approximate share price of $0.16 per share for a total issuance of 17,686,274 common shares of ProMetic which are subject to a four month hold period. During May 2011, ProMetic Biosciences Limited, a subsidiary of the Company, secured an interest free, repayable working capital grant from the Isle of Man Government department of Economic Development for the sum of GBP 300,000 ($474). This sum is repayable in six equal instalments starting 6 months from the date of the draw down of the grant. The funds have been granted for working capital purposes in ProMetic Biosciences Ltd. The Company also granted a total of 3,200,000 restricted share units (“RSUs”) to certain executive officers of the Company, as part of an incentive program design to align the interests of its executives with those of its shareholders, and in accordance with its Long Term Incentive Plan (“LTIP”). The RSUs only vest upon achievement of various important corporate and commercial objectives that would create significant shareholder value. 13

14. ProMetic Life Sciences Inc. 14 Introduction – Forward Looking StatementFinancials Q1 2011Protein Technologies Business Review & OutlookTherapeutics Business Review & OutlookSummaryQ&A

15. Lead Drug Candidates Multiple Opportunities 15 PBI-4419PBI-4050 Cancer Indications e.g. pancreas leukemia Anemia in cancer patients (CIA, CRA) Anemia in renal patients (CKD, ESRD) Fibrosis Indications (CKD, ESRD, AKI) PBI-1402

16. 16 Cancer Indications e.g. pancreas leukemia Anemia in cancer patients (CIA, CRA) PBI-1402 Mastocytoma P815 cells express both EPO and PBI-1402 receptors. EPO increases the percentage of mice bearing liver metastasis while PBI-1402 reduces it (dose dependent). * *

17. CONFIDENTIAL 17 17 Diabetes CKD Hypertension Anemia End Stage Renal Disease Diabetes nephropathy Dialysis Cardiovascular Complications Facts About Chronic Kidney Disease (CKD) 26 million Americans have CKD and millions of others are at increased risk Risk Factors Heart disease is the major cause of death for all people with CKD Fibrosis = progression of CKD to kidney failure Hypertension causes CKD CKD causes hypertension

18. CONFIDENTIAL 18 18 Diabetes CKD Hypertension Anemia End Stage Renal Disease Risk factors Diabetes nephropathy Dialysis Cardiovascular Complications Risk Factors PBI-4050 PBI-4419

19. ProMetic Life Sciences Inc. 19 Introduction – Forward Looking StatementFinancials Q1 2011Protein Technologies Business Review & OutlookTherapeutics Business Review & OutlookSummaryQ&A

20. Blue Chip Clients 20 Worldwide exclusive agreement for Protein Technologies for restricted fields On-going supply of affinity resin Celgene Deal 20

21. Origin of vCJD Late 1970’s First cases of BSE identified; feed ban introduced 1988 Changes to preparation of meat and bone meal used in animal feed Government assures the public British beef safe for human consumption First case of vCJD identified Link between BSE and vCJD made; 30 month cull initiated 1986 1990 19951996 First vCJD transfusion transmission case identified 2003

22. Sir Paul Beresford: To ask the Secretary of State for Health (1) pursuant to the answer of 24 March 2011, Official Report, column 1273W, on blood transfusions, whether the dates for the timetabling of the prion filtered red blood cells in surgery and multi-tansfused patients (PRISM) study have changed; and when he expects the final report to be completed; (2) whether the eight-week antibody tests of the prion filtered red blood cells in surgery and multi- transfused patients (PRISM) study have been concluded. Anne Milton: The timetable remains as set out in my reply of 24 March 2011, Official Report, column 1273W. The final report will be completed by the end of December 2011, for consideration by the Advisory Committee on the Safety of Blood, Tissue and Organs in early 2012. I understand that the study in multi-transfused patients will no longer go ahead due to difficulties in recruiting sufficient patients to the study. As of 3 June 2011, eight-week antibody samples continue to be received from surgical patients, as part of the prion filtered red cells in surgery and multi-transfused patients study. The samples are taken eight weeks after the patients receive the red cell units, and follow-up samples taken at six months. Sir Paul Beresford: To ask the Secretary of State for Health what estimate he has made of the costs of the (a) development and (b) implementation of (i) prion filtration and (ii) a blood test for vCJD. Anne Milton: With regard to prion filtration I refer the hon. Member to the written answer I gave the hon. Member for Ogmore (Huw Irranca-Davies) on 23 May 2011, Official Report, column 423W. Costs of development are borne by manufacturers. With regard to blood tests no estimates have been made of the costs of the development and implementation of a blood test for variant Creutzfeldt-Jakob disease (vGD) as there is currently no test proven to identify asymptomatic vCJD infection. June 13, 2011 – House of Commons, UK Written questions from Sir Paul Beresford answered:

23. Red Blood Cells concentrate SaBTO November 09 recommendations for Red Blood Cell concentrates: To use P-Capt® for transfusion in children < 14 years PRISM study: transfusion of P-Capt filtered red cells (Target 270 patients + 270 controls). March 2011: 329 patients transfused with 942 units of prion-filtered RCC; 273 control patients transfused with normal red cells. No Serious Adverse Events reported. …..final report will be completed by the end of December 2011, for consideration by the SaBTO in early 2012 (extract, answer to written question by Anne Milton, House of Commons, England – June 13 2011)

24. Distribution of TSE infectivity in blood

25. 25 Industrial applications Commercial use for manufacture of prion- reduced SD Plasma (Octaplas LG®; Uniplas®). Octaplas LG now approved in 4 countries (Germany, Switzerland, Portugal & Australia) with several more approvals pending. ProMetic is currently working with >10 companies on industrial applications of PRDT technology.

26. Orphan Rxµg $ 000 000 / g N/A >70% Coagulationµg $ 000 000 / g 20% ~50% Factors Plasminogen / mg $ 000 / g 35% 90% Plasmin Alpha 1 anti- Trypsing $300 / g 23% 86% Fibrinogeng 40% 91% IgG ~8 g $70/g 70% 93% Albumin ~35 g $3/g 82% 79% Products Concentration/commercial value Yield Yield L plasmaper gram of protein Cohn PPPS Chart illustrating how PPPS™ yield advantage impact on overall output value per L of plasma processed

27. ProMetic’s Laval facility Recovery of therapeutic proteins from plasma 150,000 litre annual plasma capacity cGMP facility cGMP clinical trial supplies Conformance lots post BLA Initial commercial requirements Supply bulk active proteins to partners Provide validated blue print for partners’ future plants Technology showroom and training of partners’ staff Technology transfer at scale Functional H1 2012 First IND filings 2012 ProMetic’s new facility in Laval, Quebec, 2011 27

28. Wuhan Institute of Biological Products WIBP located in Wuhan 60 years experience in the fields of biomedical research and product development; 1,200 employees >24 vaccines and plasma derivatives currently marketed throughout the China. China National Biotech Group Headquartered in Beijing, state-owned enterprise the largest biopharmaceutical company in China. CNBG is the largest producer of vaccines and blood derivatives in China, enjoying more than 80% and 30% market share respectively. The company consists of 6 Institute of Biological Products. >9,000 employees, 28

29. WIBP - newly built plasma production facility where PPPS™ is implemented

30. Production area in WIBP new plasma facility

31. Increased investment in China for the advancement of the PPPS™ manufacturing platform which will significantly expand the resources deployed for the benefit of both CNBG/WIBP and ProMetic; Intensification of the development program so that more plasma-derived products can be developed simultaneously and at an accelerated pace; ProMetic's new manufacturing facility in Laval, Quebec becoming a strategic platform for WIBP/CNBG; Reciprocal technology transfer between WIBP/CNBG and NewCo regarding new manufacturing processes and products being scaled up in China and Canada. The original scientific collaboration between the two companies expanded to also include engineering and manufacturing involving the new facilities in Laval (Canada) and in Wuhan (China);

32. Turn-key process for Best-in-class Therapeutics derived from plasma 32 Human plasma - pooled for batch process cGMP Manufacturing process Pure Bulk Active Ingredient Finished Dosage form Protein extraction Prion- removal

33. ProMetic Life Sciences Inc. 33 Introduction – Forward Looking StatementFinancials Q1 2011Therapeutics Business Review & OutlookProtein Technologies Business Review & OutlookSummaryQ&A

34. ProMetic Life Sciences Inc. 34 Introduction – Forward Looking StatementFinancials Q1 2011Therapeutics Business Review & OutlookProtein Technologies Business Review & OutlookSummaryQ&A

35. ProMetic Life Sciences Inc. 35 Introduction – Forward Looking StatementFinancials Q1 2011Therapeutics Business Review & OutlookProtein Technologies Business Review & OutlookSummaryQ&A